FORGOTTEN HISTORY: Drts - The Untold Story

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears

Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company’s most important trials are “coming to a head” over the coming months. Levy said the company is

MarketBeat · May 29

Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study

Alpha Tau Medical (NASDAQ:DRTS) presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical investigators describing initial tumor responses and safety observations from the pilot trial. Th

MarketBeat · May 11